H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Agenus (AGEN – Research Report) today and set a price target of $8.00. The company’s shares opened today at $1.37.
According to TipRanks, Bodnar is an analyst with an average return of -8.4% and a 35.14% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as Agenus, Gracell Biotechnologies, and Sana Biotechnology.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Agenus with a $7.66 average price target.
See the top stocks recommended by analysts >>
Based on Agenus’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $22.9 million and a GAAP net loss of $68.25 million. In comparison, last year the company earned a revenue of $25.94 million and had a GAAP net loss of $48.33 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes AGEN1884, AGEN2034, INCAGN1876, INCAGN1949, Prophage, AutoSynVax, PhosphoSynVax, and AS-21 Stimulon. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.
Read More on AGEN:
- AGEN Earnings this Week: How Will it Perform?
- Jasper Therapeutics appoints Carlos as SVP, Marcantonio as VP
- Agenus names Robin Taylor, Homa Yeganegi, Stephanie Fagan to executive team
- Agenus reports data from Phase 1b trial of botensilimab/balstilimab combination
- Agenus files automatic mixed securities shelf
